Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280252 | 0.81 | PTGDR2 (0.45) | CA5APTGDR2PTGDRCYP3A4ALDH1A1 | |
| Benzene SCHEMBL2275811 | 0.78 | PTGDR2 (0.51) | CA5APTGDR2PTGDRCYP3A4ALDH1A1 | |
| SCHEMBL2275799 | 0.76 | PTGDR2 (0.49) | CA5APTGDR2PTGDRCYP3A4ALDH1A1 | |
| SCHEMBL21328360 | 0.75 | GAA (0.70) | CA5APTGDR2CYP3A4ALDH1A1LMNA | |
| SCHEMBL21328347 | 0.72 | CA5A (0.66) | CA5ACYP3A4ALDH1A1LMNANPSR1 | |
| SCHEMBL350065 | 0.72 | CYP3A4 (0.51) | CA5APTGDR2PTGDRCYP3A4ALDH1A1 | |
| SCHEMBL2503430 | 0.72 | PTGDR2 (0.56) | PTGDR2PTGDRCYP3A4 | |
| Benzene SCHEMBL2280257 | 0.71 | PTGDR2 (0.46) | CA5APTGDR2PTGDRCYP3A4ALDH1A1 | |
| SCHEMBL2280248 | 0.71 | CHRM1 (0.46) | CA5APTGDR2PTGDRCYP3A4ALDH1A1 | |
| SCHEMBL21328344 | 0.69 | GAA (0.70) | CA5APTGDR2ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CA5A 2008/4885PTGDR2 2/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.